Key result
Early atorvastatin after pediatric heart transplant linked to ~33% greater 5-year freedom from GCAD.
Why the study?
The preventative effects of HMG-coenzyme A reductase inhibitors against pediatric graft coronary artery disease after cardiac transplantation are not well known.
Does early initiation of atorvastatin prevent graft coronary artery disease in pediatric cardiac transplant recipients?
Cohort
Single-blind
Does early initiation of atorvastatin prevent graft coronary artery disease in pediatric cardiac transplant recipients?
Early initiation of atorvastatin in pediatric cardiac transplant recipients is associated with significantly higher freedom from graft coronary artery disease and fewer early rejection episodes.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in pediatric heart transplant; leaves open whether RCTs will confirm early atorvastatin prevents graft coronary artery disease.
Graft coronary artery disease is a significant cause of late graft failure and death after cardiac transplantation. HMG-coenzyme A reductase inhibitors have been used safely in children but their preventative effects against GCAD are not well known. We investigated whether atorvastatin when initiated early could prevent against the development of pediatric GCAD. Pediatric patients (transplanted between October 28, 1992 and July 9, 2004) were stratified into two groups based on whether or not they received atorvastatin early after transplant. Angiograms were reviewed by a single observer blinded to the treatment strategies and clinical outcomes. Actuarial survival method and the Mantel-Cox test were used to assess statistical significance. Freedom from GCAD was higher among those treated with atorvastatin early in the post-transplant course. One, three, and five-yr freedom from GCAD was significantly greater in the early treatment group (97%, 93%, and 93% respectively) compared with the control group (72%, 65%, and 60% respectively, p < 0.005). The early treatment group was also noted for fewer rejection episodes in the first post-transplant year. The use of atorvastatin when initiated early in the post-transplant course appears protective against graft coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Chin et al. (2007) conducted a cohort in Pediatric graft coronary artery disease. Atorvastatin vs. Control group was evaluated on 5-year freedom from graft coronary artery disease (p=< 0.005). Early initiation of atorvastatin after pediatric cardiac transplantation was associated with greater 5-year freedom from graft coronary artery disease compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: